These events highlight the accelerated pace of this litigation and narrowed the focus to the evidence: what was known and knowable, when it was known or should have been known, and what patients and physicians were told about this drug.”
From Allegations To Evidence
The Depo-Provera litigation centers on whether women received timely and adequate information about risks associated with Depo-Provera— particularly the risk of developing intracranial meningiomas. Although often described as benign, these tumors and their treatment can cause serious and lasting harm, including seizures, vision impairment, and cognitive changes. Many require invasive brain surgery, and plaintiffs frequently live with permanent, life-altering injuries.
The lawsuits allege that manufacturers failed to adequately warn patients and prescribing physicians about this risk, even as scientific literature and safety signals increasingly linked medroxyprogesterone acetate— the active ingredient in Depo- Provera— to greatly elevated meningioma risk.
What has changed is not the factual foundation underlying these women’ s claims, but the posture of the case. The litigation is no longer about whether these concerns warrant scrutiny. It is now about how the evidence will be developed, tested, and ultimately evaluated on an expedited track after the FDA recognized this very serious danger.
The Revised Warning Label— And What It Means
In December 2025, the FDA approved a meningioma warning on Depo-Provera’ s label. That regulatory action is consequential. The updated labeling acknowledges reported cases of meningioma following use of injectable Depo-Provera, particularly with long-term exposure, and advises clinicians to discontinue treatment if a meningioma is diagnosed. The agency’ s decision— and the approval of warning language on Pfizer’ s second submission— adds weight to the reality of the risk and the expectation that it be disclosed.
Regulatory action does not decide civil liability. However, it provides critical context. A mandated warning confirms that the risk at the center of this litigation is real, scientifically supported, and significant enough to require express disclosure. For patients who say they were never informed, the label change amplifies the central question in these cases: whether meaningful warnings should have been provided earlier— when patients were making decisions and physicians were prescribing Depo-Provera.
From a litigation perspective, the FDA’ s approval of a meningioma warning intersects directly with failure-to-warn claims and ongoing preemption arguments. Pfizer has, from the start, asserted that federal regulation constrained its ability to strengthen warnings independently. The Court will decide how those arguments apply. The development of a comprehensive evidentiary record thus becomes even more vital to the case: what was known, when it was known, how safety signals evolved, and how risk information was handled over time.
Structure And Leadership In The MDL
Centralization in an MDL such as this one provides an organized and efficient framework for resolving common factual and legal issues. It also compresses the timeline in a way that individual cases rarely do— especially in this MDL since the Court set a firm trial date early in the proceeding.
In March 2025, the Court appointed me Plaintiffs’ Executive Committee Co-Chair and Trial Subcommittee Member in the Depo-Provera MDL. These committees play critical roles in coordinating strategy, managing discovery, briefing common motions, negotiating resolution where appropriate, and communicating with the Court on behalf of all plaintiffs in the MDL. The highly experienced lead counsel, co-leads and the entire talented and dedicated leadership team members have, across the board, worked tirelessly to do top level work on behalf of the Plaintiffs.
That work is already well underway. The Court permitted discovery directed to matters of preemption and general causation. MDL discovery allows focused review of applicable scientific research, internal communications, and regulatory interactions that bear directly on what warnings were given, when they were considered, and how risk information was communicated to patients and clinicians.
A Trial Date Changes The Pace
The December 2026 trial date has put real momentum behind the MDL— particularly given how recently the proceeding was formed and how quickly the Court moved to set the first trial. In complex litigation, a date on the calendar does what nothing else can: it forces focus. It accelerates expert development, narrows disputes, and drives discovery toward the issues that will actually be tried.
As that date approaches, the Court and the parties will address issues common to pharmaceutical MDLs, including general causation, expert admissibility, and case specific discover. Those steps will help test the claims and defenses through evidence and will shape whether the litigation resolves through settlement, trial, or both.
Addressing Defense Arguments
Defendants have indicated they will press federal preemption of claims and other defenses. Those issues will be resolved through arguments, briefing, and judicial rulings, not by sound bites. At this stage, what matters is ensuring the Court has a complete factual record— developed through discovery and tested through expert analysis.
The Trial Lawyer 65